Mibavademab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Mibavademab
- IMMUNOGLOBULIN G4 (227-PROLINE), ANTI-(HUMAN LEPTIN RECEPTOR) (HUMAN MONOCLONAL REGN4461 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN4461 .KAPPA.-CHAIN, DIMER
- immunoglobulin g4 227 proline anti human leptin receptor human monoclonal regn4461 gamma 4 chain disulfide with human monoclonal regn4461 kappa chain dimer
- mibavademab
- Mibavademab
- mibavademab [INN]
- mibavademab inn
- regn 4461
- REGN-4461
- regn4461
- Regn4461
- REGN4461
- CAS registry numbers
- 2305770-44-7
- ChEMBL ID
- CHEMBL4650509
- FDA ingredient codes (UNII)
- PHL2UDY3AB
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -mab
Mechanisms of action
- Mechanism
- Leptin receptor agonist
- Action type
- Agonist
- Target
- Leptin receptor
- Protein identifier
- P48357
Open Targets mechanisms
- Mechanism
- Leptin receptor agonist
- Action type
- Agonist
- Target
- Leptin receptor
Investigated indications
- Condition
- Lipodystrophy, Congenital Generalized
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0027766
- Subject identifier
- D052497
- Condition identifier
- EFO_1000727
- Condition identifier
- HP_0001513
- Highest recorded phase
- 3
- Condition identifier
- HP_0003074
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005347
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019182
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0020088
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0027766
- Highest recorded phase
- 3
Trial references
- NCT04159415
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (8)
- A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
- A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
- A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
- A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers
- A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
- Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
- Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
In development for (2)
- Generalized lipodystrophy Phase 2
- Inherited obesity Phase 3
Other linked conditions (1)
- Lipodystrophy
Targets (1)
- LEPR Leptin receptor agonist